---
schema_version: "secwatch.filing_event.v1"
accession: "0001539497-22-000063"
form_type: "8-K"
ticker: "BIXT"
cik: "0001445815"
company_name: "BIOXYTRAN, INC"
filed_at: "2022-01-14T23:59:59+00:00"
generated_at: "2026-06-27T17:53:45.507871+00:00"
event_type: "debt"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Bioxytran issues $1.467M in 1-year 6% convertible notes at $0.25; also releases corporate presentation

## Summary
- Entered 34 Note Purchase Agreements for $1,467,000 principal in convertible notes due Jan 10, 2023; 6% interest, conversion at $0.25/share.
- Net cash reduced by $86,040; aggregate discount of $128,290 includes 264,060 five-year warrants at $0.25 issued to placement agent WallachBeth Capital.
- Board approved the agreements on Jan 10, 2022; notes issued same day.
- Filed corporate presentation (Exhibit 99.1) on Jan 12, 2022 outlining pharmaceutical development status (no specific content provided).

## SEC filing metadata
- accession: 0001539497-22-000063
- form_type: 8-K
- ticker: BIXT
- cik: 0001445815
- company_name: BIOXYTRAN, INC
- filed_at: 2022-01-14T23:59:59+00:00
- event_type: debt
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 1.01, 3.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1445815/000153949722000063/0001539497-22-000063-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1445815/000153949722000063/n2583_x16-8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001539497-22-000063
- JSON: https://secwatch.observer/filing/0001539497-22-000063.json
- Plain text: https://secwatch.observer/filing/0001539497-22-000063.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.